Warner Chilcott PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Warner Chilcott PLC
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights AI trends in medtech, Exec Chats with iRhythm and medical robotics authority Moshe Shoham, and key FDA updates.
Minute Insight: Viz.ai Raises $100M To Expand AI-Based Platform To Detect Diseases, Coordinate Care In Hospitals
The latest funding round, led by Tiger Global Management and Insight Partners, values the company at $1.2bn.
Private Company Edition: Westlake Village BioPartners-founded Neuron23 will take the LRRK2 inhibitor NEU-723 for Parkinson’s disease into human testing before the end of 2022. Also, Celsius raised $83m in fresh VC cash and ITM added another €33m to its recent €25m equity financing.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
- Other Names / Subsidiaries
- Galen Holdings PLC